These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 6734034)

  • 1. Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism.
    Dahlqvist R; Bertilsson L; Birkett DJ; Eichelbaum M; Säwe J; Sjöqvist F
    Clin Pharmacol Ther; 1984 Jun; 35(6):815-21. PubMed ID: 6734034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
    Eichelbaum M; Bertilsson L; Säwe J
    Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deficient metabolism of debrisoquine and sparteine.
    Inaba T; Otton SV; Kalow W
    Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
    Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
    Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
    Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.
    Bertilsson L; Eichelbaum M; Mellström B; Säwe J; Schulz HU; Sjöqvist F
    Life Sci; 1980 Nov; 27(18):1673-7. PubMed ID: 7442467
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine.
    Otton SV; Inaba T; Mahon WA; Kalow W
    Can J Physiol Pharmacol; 1982 Jan; 60(1):102-5. PubMed ID: 7066751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
    Eichelbaum M; Bertilsson L; Säwe J; Zekorn C
    Clin Pharmacol Ther; 1982 Feb; 31(2):184-6. PubMed ID: 7056024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.
    Gross AS; Mikus G; Fischer C; Hertrampf R; Gundert-Remy U; Eichelbaum M
    Br J Clin Pharmacol; 1989 Nov; 28(5):555-66. PubMed ID: 2511912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacogenetics of sparteine and debrisoquine.
    Inaba T; Vinks A; Otton SV; Kalow W
    Clin Pharmacol Ther; 1983 Mar; 33(3):394-9. PubMed ID: 6825393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
    Schellens JH; van der Wart JH; Brugman M; Breimer DD
    J Pharmacol Exp Ther; 1989 May; 249(2):638-45. PubMed ID: 2724144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
    Evans DA; Harmer D; Downham DY; Whibley EJ; Idle JR; Ritchie J; Smith RL
    J Med Genet; 1983 Oct; 20(5):321-9. PubMed ID: 6644761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state.
    Teunissen MW; De Leede LG; Boeijinga JK; Breimer DD
    J Pharmacol Exp Ther; 1985 Jun; 233(3):770-5. PubMed ID: 4009489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.
    Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C
    Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.
    Meyer UA; Skoda RC; Zanger UM
    Pharmacol Ther; 1990; 46(2):297-308. PubMed ID: 2181495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipyrine metabolism in female Lewis and Dark Agouti strains of rats, which are extensive and poor metabolizers of debrisoquine, respectively.
    Tanaka E; Kobayashi S; Uchida E; Oguchi K; Yasuhara H
    Jpn J Pharmacol; 1989 Mar; 49(3):433-5. PubMed ID: 2747044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.
    Eichelbaum M; Gross AS
    Pharmacol Ther; 1990; 46(3):377-94. PubMed ID: 2188269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.
    Brøsen K; Hansen JG; Nielsen KK; Sindrup SH; Gram LF
    Eur J Clin Pharmacol; 1993; 44(4):349-55. PubMed ID: 8513845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.